Esperion Therapeutics, Inc. (FRA:0ET)

Market Cap	671.77M +58.7%
Revenue (ttm)	258.93M +2.8%
Net Income	-90.20M
EPS	-0.46
Shares Out	n/a
PE Ratio	n/a
Forward PE	10.21
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	675
Open	2.654
Previous Close	2.513
Day's Range	2.654 - 2.654
52-Week Range	0.478 - 3.504
Beta	n/a
RSI	49.72
Earnings Date	Mar 3, 2026

About Esperion Therapeutics

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company’s marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LD...

• Industry: Pharmaceutical Preparations
• Founded: 2008
• Employees: 304
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0ET

Financial Performance

In 2024, Esperion Therapeutics's revenue was $332.31 million, an increase of 185.66% compared to the previous year's $116.33 million. Losses were -$51.75 million, -75.27% less than in 2023.

Financial numbers in USD